# Geert D’Haens

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/geert-d-haens/

## Facts

| Field | Value |
| --- | --- |
| Citations | 76,024 |
| Field | Inflammatory Bowel Disease |
| h-index | 125 |
| i10-index | 577 |
| Last Known Institution | Amsterdam UMC Location University of Amsterdam |
| OpenAlex ID | https://openalex.org/A5057899912 |
| ORCID iD | https://orcid.org/0000-0003-2784-4046 |
| Works | 1,607 |

## Researcher papers

Showing 12 of 14.

- [Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target](https://scholariq.org/papers/selecting-therapeutic-targets-in-inflammatory-bowel-disease-stride-determining/)
- [Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/tofacitinib-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations](https://scholariq.org/papers/the-second-european-evidence-based-consensus-on-the-diagnosis-and-management-of/)
- [Development of the Crohnʼs disease digestive damage score, the Lémann score](https://scholariq.org/papers/development-of-the-crohn-s-disease-digestive-damage-score-the-lemann-score/)
- [Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study](https://scholariq.org/papers/effects-of-adalimumab-therapy-on-incidence-of-hospitalization-and-surgery-in/)
- [Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial](https://scholariq.org/papers/laparoscopic-ileocaecal-resection-versus-infliximab-for-terminal-ileitis-in/)
- [Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection](https://scholariq.org/papers/infliximab-reduces-endoscopic-but-not-clinical-recurrence-of-crohn-s-disease/)
- [Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis](https://scholariq.org/papers/efficacy-and-safety-of-vedolizumab-subcutaneous-formulation-in-a-randomized/)
- [Development of the Lémann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease](https://scholariq.org/papers/development-of-the-lemann-index-to-assess-digestive-tract-damage-in-patients/)
- [A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial](https://scholariq.org/papers/a-biomarker-stratified-comparison-of-top-down-versus-accelerated-step-up/)
- [IL-12 and IL-23 pathway inhibition in inflammatory bowel disease](https://scholariq.org/papers/il-12-and-il-23-pathway-inhibition-in-inflammatory-bowel-disease/)
- [Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease](https://scholariq.org/papers/deep-remission-at-1-year-prevents-progression-of-early-crohn-s-disease/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Autoimmune and Inflammatory Disorders](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders/)
- [Eosinophilic Esophagitis](https://scholariq.org/topics/eosinophilic-esophagitis/)

## Researcher university

- [Amsterdam UMC Location University of Amsterdam](https://scholariq.org/institutions/amsterdam-umc-location-university-of-amsterdam/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.